» Articles » PMID: 24596084

A Multicenter Randomized Controlled Trial of Tonsillectomy Combined with Steroid Pulse Therapy in Patients with Immunoglobulin A Nephropathy

Abstract

Background: The study aim was, for the first time, to conduct a multicenter randomized controlled trial to evaluate the effect of tonsillectomy in patients with IgA nephropathy (IgAN).

Methods: Patients with biopsy-proven IgAN, proteinuria and low serum creatinine were randomly allocated to receive tonsillectomy combined with steroid pulses (Group A; n = 33) or steroid pulses alone (Group B; n = 39). The primary end points were urinary protein excretion and the disappearance of proteinuria and/or hematuria.

Results: During 12 months from baseline, the percentage decrease in urinary protein excretion was significantly larger in Group A than that in Group B (P < 0.05). However, the frequency of the disappearance of proteinuria, hematuria, or both (clinical remission) at 12 months was not statistically different between the groups. Logistic regression analyses revealed the assigned treatment was a significant, independent factor contributing to the disappearance of proteinuria (odds ratio 2.98, 95% CI 1.01-8.83, P = 0.049), but did not identify an independent factor in achieving the disappearance of hematuria or clinical remission.

Conclusions: The results indicate tonsillectomy combined with steroid pulse therapy has no beneficial effect over steroid pulses alone to attenuate hematuria and to increase the incidence of clinical remission. Although the antiproteinuric effect was significantly greater in combined therapy, the difference was marginal, and its impact on the renal functional outcome remains to be clarified.

Citing Articles

Post-transplant glomerular diseases: update on pathophysiology, risk factors and management strategies.

Regalia A, Abinti M, Alfieri C, Campise M, Verdesca S, Zanoni F Clin Kidney J. 2024; 17(12):sfae320.

PMID: 39664990 PMC: 11630810. DOI: 10.1093/ckj/sfae320.


Investigating potential drug targets for IgA nephropathy and membranous nephropathy through multi-queue plasma protein analysis: a Mendelian randomization study based on SMR and co-localization analysis.

Xu X, Miao C, Yang S, Xiao L, Gao Y, Wu F BioData Min. 2024; 17(1):49.

PMID: 39516845 PMC: 11545554. DOI: 10.1186/s13040-024-00405-w.


A case of renal hypouricemia due to T217M mutation in SLC22A12 incidentally associated with IgA nephropathy.

Sakurabu Y, Uchida H, Tahara T, Asakawa T, Yamasaki H, Katayama K Clin Case Rep. 2024; 12(9):e9368.

PMID: 39206069 PMC: 11349819. DOI: 10.1002/ccr3.9368.


Contemporary review of IgA nephropathy.

Filippone E, Gulati R, Farber J Front Immunol. 2024; 15:1436923.

PMID: 39188719 PMC: 11345586. DOI: 10.3389/fimmu.2024.1436923.


Effect of tonsillectomy combined with steroid pulse therapy upon IgA nephropathy depending on proteinuria status at diagnosis: a nationwide multicenter cohort study in Japan.

Komatsu H, Fujimoto S, Sato Y, Yasuda T, Yasuda Y, Matsuzaki K Clin Exp Nephrol. 2024; 28(12):1272-1281.

PMID: 38954311 PMC: 11621197. DOI: 10.1007/s10157-024-02530-6.


References
1.
Appel G, Waldman M . The IgA nephropathy treatment dilemma. Kidney Int. 2006; 69(11):1939-44. DOI: 10.1038/sj.ki.5000434. View

2.
Bartosik L, Lajoie G, Sugar L, Cattran D . Predicting progression in IgA nephropathy. Am J Kidney Dis. 2001; 38(4):728-35. DOI: 10.1053/ajkd.2001.27689. View

3.
Julian B, Barker C . Alternate-day prednisone therapy in IgA nephropathy. Preliminary analysis of a prospective, randomized, controlled trial. Contrib Nephrol. 1993; 104:198-206. View

4.
Alamartine E, Sabatier J, Guerin C, Berliet J, Berthoux F . Prognostic factors in mesangial IgA glomerulonephritis: an extensive study with univariate and multivariate analyses. Am J Kidney Dis. 1991; 18(1):12-9. DOI: 10.1016/s0272-6386(12)80284-8. View

5.
Wang Y, Chen J, Wang Y, Chen Y, Wang L, Lv Y . A meta-analysis of the clinical remission rate and long-term efficacy of tonsillectomy in patients with IgA nephropathy. Nephrol Dial Transplant. 2010; 26(6):1923-31. DOI: 10.1093/ndt/gfq674. View